36
Participants
Start Date
April 6, 2016
Primary Completion Date
November 2, 2017
Study Completion Date
August 28, 2020
Talimogene Laherparepvec
The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
Pembrolizumab
Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
Research Site, Brussels
Research Site, Geneva
Research Site, Wilrijk
Research Site, Melbourne
Research Site, Geelong
Research Site, Salzburg
Research Site, Bellinzona
Research Site, Zurich
Research Site, New York
Research Site, New York
Research Site, Athens
Research Site, Newark
Research Site, Milan
Research Site, Madrid
Research Site, Madrid
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Louisville
Research Site, Seville
Research Site, Canton
Research Site, Ioannina
Research Site, Billings
Research Site, Chicago
Research Site, Chicago
Research Site, Pierre-Bénite
Research Site, Toronto
Research Site, L'Hospitalet de Llobregat
Research Site, Birmingham
Research Site, London
Research Site, London
Research Site, Metropolitan Borough of Wirral
Research Site, Oxford
Research Site, Sutton
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Amgen
INDUSTRY